Download PDF

Register to download the report. Already a member?

 
 
Sign Up

Or

61509 1497862462HCLSReviewTaiwanJune2017.pdf
Energy Boardroom

Another Glaxo respiratory drug sees regulatory filings in its future

13.03.2014 / Fierce Pharma

The British pharma giant says it's nailed the primary endpoint in a Phase III study of its injectable candidate mepolizumab, which will help set the severe eosinophilic asthma treatment up for its first regulatory filings.

LATEST ISSUE

DOWNLOAD

X
Download PDF

First Name:

Last Name:

Company:

Position:

Country:

Email: